KYMA Device: External Measure of Thoracic Fluid and Vital Signs (Ease)

External measure of thoracic fluid content (TFC) combined with vital signs (HR,respiratory rate(RR), posture and movements) using the technology developed by Kyma Medical Technologies while tracking clinical changes in acute in-hospital and chronic outpatient heart failure patients.

Study Overview

• Status: Completed
• Conditions: Congestive Heart Failure(CHF)
• Intervention / Treatment: Device: Kyma Device u-Cor System

Detailed Description

This is a prospective, single center, non-randomized study designed to correlate Kyma measurements and in-hospital parameters as well as the changes in TFC and vital signs with clinical changes in the outpatient setting for 60 days post-discharge. The patient and hospital study personnel will be blinded to the Kyma data captured by the device. No intervention will be performed on the patient based on the Kyma device data, this is an observational study.

The goals of the study are:

1. Follow thoracic fluid and vital signs in acute, hospitalized heart failure(HF) patients with evidence of volume overload to evaluate this combined parameter in relation to decongestion (time to clear lung auscultation or clearing of congestion on chest x-ray or decrease in BNP by 50%), clinical symptoms, physical exam, and biomarker results.
2. Evaluate the relationship between lung decongestion as externally measured and hemodynamic parameters as measured by pulmonary artery catheter in a subset of patients
3. Correlate changes in thoracic fluid content and vital signs with clinical changes in the outpatient setting for 60 days post-discharge.
4. Evaluate the feasibility of implementing a physician-directed, patient- managed model of diuretic and vasodilator adjustment.

Patients will be approached for enrollment within 24 hours of presentation to the hospital. The Kyma device will be applied to the patient. Data will be automatically collected by the device: TFC will be measured every 30 minutes and vital signs will be measured several times an hour.

Information collected at baseline by the study coordinators will include medications, lab work (CBC, Chemistry, BNP), ejection fraction(EF), weight, vital signs, and lung auscultation for both Cohorts.

Cohorts I and II may be enrolled concurrently. For patients enrolled in Cohort I, PA readings will be recorded at baseline and 3 times daily until the pulmonary artery(PA) catheter is removed.

While hospitalized, all patients will have daily weights, intake/output, Physical Exams(edema, jugular venous distention(JVP), lung exam) and vital signs will be recorded twice daily. Lab results will be recorded as well as any changes in medication.

After hospital discharge, the patients will wear the Kyma device for an additional 60 days. Patients will be contacted by telephone at 10 days, 30 days, and 60 days post-discharge for weight measurements, medication changes, and assessment of any Office Visits, or ER/Hospitalizations for SOB.

The Minnesota Living with Heart Failure Questionnaire will be administered at hospital discharge and 30 and 60 days post-discharge.

• Study Type: Interventional
• Enrollment (Actual): 17
• Phase: Not Applicable

Contacts and Locations

Study Locations

• United States
  • Ohio
    • Cincinnati, Ohio, United States, 45219
      • The Lindner Research Center at The Christ Hospitak

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

• Cohort I

  1. Men or women over 18 years of age
  2. Admitted for primary diagnosis of HF
  3. Already assigned for indwelling PA catheter monitoring
  4. BNP > 400
  5. Two of the following: edema, JVP>7cm, rales
  6. Currently being assessed with clinically indicated hemodynamic monitoring

Cohort II

1. Men or women over 18 years of age
2. Admitted with the primary diagnosis of HF
3. BNP > 400
4. Two of the following: edema, JVP> 7cm, rales
5. Patients with or without hemodynamic monitoring in use

Exclusion Criteria:

Cohort I and II

1. Patients with allergies or skin sensitivities to electrode hydrogel and/or acrylic based adhesive
2. Pregnant women

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Diagnostic
• Allocation: Non-Randomized
• Interventional Model: Single Group Assignment
• Masking: Triple

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Cohort I; Patients admitted with the primary diagnosis of HF and are currently being assessed with clinically indicated hemodynamic monitoring.The Kyma device will be worn by the patient and data collected from the device will be compared to the data collected through hemodynamic monitoring. The device will be worn for 60 days post hospital discharge.	Device: Kyma Device u-Cor System; The Kyma uCor system externally measures thoracic fluid content, heart rate, respiratory rate, posture and movement. The system includes a flat antenna that is attached to the patient's torso with a bandage-like sticker. The antenna transmits radio waves and receives their reflections from the body for several seconds every few hours throughout the day.The data is recorded and collected then compared to traditional clinical parameters.
Experimental: Cohort II; Patients admitted with the primary diagnosis of HF and are being assessed with or without hemodynamic monitoring. The Kyma device will be worn by the patient and data collected from the device will be compared to the data collected while the patient is hospitalized. The device will be worn for 60 days post hospital discharge.	Device: Kyma Device u-Cor System; The Kyma uCor system externally measures thoracic fluid content, heart rate, respiratory rate, posture and movement. The system includes a flat antenna that is attached to the patient's torso with a bandage-like sticker. The antenna transmits radio waves and receives their reflections from the body for several seconds every few hours throughout the day.The data is recorded and collected then compared to traditional clinical parameters.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Validate the ability of externally monitored thoracic fluid content as a measure of HF.	Accomplished by comparing the data measured by the Kyma Device(HR, RR, thoracic fluid content) with the same clinical data collected while in the hospital.	60 days

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Assess the effectiveness of remote monitoring in detecting outpatient decompensation.	Compare the data collected by the Kyma Device (HR, RR, movement, thoracic fluid content) to any clinical changes related to HF in the outpatient setting.	60 days

Collaborators and Investigators

• Sponsor: The Christ Hospital
• Investigators: Principal Investigator: Eugene Chung, MD, The Lindner Research Center at The Christ Hospital

Study record dates

Study Major Dates

• Study Start: October 1, 2014
• Primary Completion (Actual): March 20, 2016
• Study Completion (Actual): April 19, 2017

Study Registration Dates

• First Submitted: October 28, 2014
• First Submitted That Met QC Criteria: February 17, 2015
• First Posted (Estimate): February 23, 2015

Study Record Updates

• Last Update Posted (Actual): July 19, 2017
• Last Update Submitted That Met QC Criteria: July 18, 2017
• Last Verified: February 1, 2015

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Heart Diseases; Cardiovascular Diseases; Heart Failure
• Other Study ID Numbers: ChristH